Delivery Order SPE2DB20D2104-SPE2DB25FMYPM
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,676.12 to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Ingrezza 40 mg capsules (30-unit quantity). This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 12, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. The contract contains no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Ingrezza 80 mg capsules (30-count units) with a contract ceiling value of $4,027.70. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the prime contractor. The order is scheduled for completion by September 30, 2025, with fulfillment occurring at the vendor's facility in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a $4,049.61 delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Ingrezza 60 mg capsules (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 23, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $4,027.70 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Ingrezza 80 mg capsules (30-count units). This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 5, 2025. The work will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. Ingrezza is a prescription medication used to treat tardive dyskinesia, a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Ingrezza 80 mg capsules (30-count units) with a ceiling value of $4,027.70. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion prime vendor agreement valued through December 2026. The award carries no set-aside designation, indicating it was...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ingrezza 40 mg capsules (30-count units) under a firm fixed-price contract valued at $7,352.24. The delivery order, issued on September 3, 2025, with an ultimate completion date of September 24, 2025, represents a non-set-aside competitive award. Performance of this contract will occur at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Ingrezza is a prescription medication used to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 17, 2025, for the supply of Ingrezza 40 mg capsules (30-count) valued at $3,676.12 with a firm fixed price structure. This non-set-aside competitive award is classified as a delivery order with an ultimate completion date of August 7, 2025, and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Ingrezza is a prescription medication used to treat involuntary...
- The Defense Logistics Agency awarded a delivery order valued at $7,352.24 to AmerisourceBergen Drug Corp for the supply of Ingrezza 40 mg capsules (30-count units). This firm fixed price, non-competitive delivery order was awarded on August 4, 2025, with an ultimate completion date of August 25, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Ingrezza is a specialized neurological medication used in the treatment of tardive dyskinesia,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Ingrezza 40 mg capsules (30-count units) valued at $3,676.12. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 18, 2025, with fulfillment occurring at the contractor's facility in Conshohocken, Pennsylvania. Ingrezza is a prescription medication used primarily for the treatment of tardive dyskinesia, a neurological movement...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $4,027.70 to supply Ingrezza 80 mg capsules (30-count packaging) with a firm fixed price structure. The award, issued on August 5, 2025, is scheduled for completion by August 26, 2025, and represents a non-set-aside, competitively awarded contract. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is a child...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMYPMDelivery Order
The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Ingrezza 40 mg capsules (quantity: 30 units) with a ceiling value of $14,704.48. This is a firm fixed-price delivery order with an ultimate completion date of September 12, 2025, and represents a non-set-aside competitive award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical supply vehicle valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen supplies a broad range of medications and medical products to support military and veteran healthcare systems. Ingrezza is an FDA-approved antipsychotic medication used in the treatment of tardive dyskinesia, and its procurement through DLA's supply chain supports the pharmaceutical needs of the Defense Health Agency and other federal healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.7k | 8/21/25 |